Low Incidence of HPV DNA in Sera of Pretreatment Cervical Cancer Patients

Overview

Journal Gynecol Oncol

Date 2001 Sep 5

PMID 11531278

Citations 14

Authors

V W Liu

P Tsang

A Yip

T Y Ng

L C Wong

H Y Ngan

Affiliations

Soon will be listed here.

Abstract

Objective: The aim of this study was to investigate the feasibility of using DNA in the circulation as a diagnostic tool for cervical cancer.

Methods: We used PCR followed by Southern hybridization to detect human papillomavirus (HPV) DNA in serum samples taken from patients of cervical cancer before treatment.

Results: A total of 60 samples were analyzed. In a set of 40 samples, without knowledge of the HPV DNA status in the corresponding cervical carcinomas, we could detect 8 (20%) positive samples, of which 7 (17.5%) were HPV 16 and 1 (2.5%) was HPV 18. In another set of 20 samples, known to be HPV 16 infected in the corresponding cervical carcinomas, we detected only 4 (20%) HPV-16-positive samples. The occurrence of HPV DNA in sera of cervical cancer patients seems sporadic.

Conclusion: The low incidence indicates that serum HPV DNA has limited application in the diagnosis of cervical cancer.

Citing Articles

The clinical utility of circulating human papillomavirus across squamous cell carcinomas.

Spindler K, Jakobsen A, Eriksen J, Fokdal L, Nordsmark M, Thorsen L Acta Oncol. 2025; 64():1-12.

PMID: 39748655 PMC: 11711493. DOI: 10.2340/1651-226X.2025.41288.

Concurrent high risk HPV35, HPV45, and HPV59 infections in prostate and bladder cancer tissues of a single patient: A case report.

Ahmed M, Cakir M, Salman N, Sandhu S, Ashrafi G Heliyon. 2024; 10(15):e35074.

PMID: 39170544 PMC: 11336358. DOI: 10.1016/j.heliyon.2024.e35074.

Cervical Cancer Genetic Profile through Circulating Tumor DNA: What Can We Learn from Blood?.

Antonouli S, Di Nisio V, Daponte N, Daponte A, Daponte A Biomolecules. 2024; 14(7).

PMID: 39062539 PMC: 11275054. DOI: 10.3390/biom14070825.

Clinical applications and utility of ctDNA in cervical cancer and its precursor lesions: from screening to predictive biomarker.

Li L, Tong Y, Wu J, Xu X Cancer Cell Int. 2023; 23(1):329.

PMID: 38110977 PMC: 10726499. DOI: 10.1186/s12935-023-03132-0.

Detection of circulating cell-free HPV DNA of 13 HPV types for patients with cervical cancer as potential biomarker to monitor therapy response and to detect relapse.

Mittelstadt S, Kelemen O, Admard J, Gschwind A, Koch A, Worz S Br J Cancer. 2023; 128(11):2097-2103.

PMID: 36973448 PMC: 10206065. DOI: 10.1038/s41416-023-02233-x.